Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

Phase 1UnknownNCT06119958

Daewoong Pharmaceutical Co. LTD.32 enrolled

Overview

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Drug Drug Interaction

Interventions

DWC202313DRUG

Experimental Drug 1

DWC202314DRUG

Experimental Drug 2

Eligibility

Sex: ALLMin age: 19 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * over 19 year old Exclusion Criteria: * Galactose intolerance * Lapp lactase deficiency

Locations (1)

H Plus YANGJI Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Cmax,ss of DWC202313 and DWC202314

Time frame: Up to 14 days

AUCt,ss of DWC202313 and DWC202314

Time frame: Up to 14 days

Secondary Outcomes

Tmax,ss of DWC202313 and DWC202314

Time frame: Up to 14 days

Cmin,ss of DWC202313 and DWC202314

Time frame: Up to 14 days

t1/2 of DWC202313 and DWC202314

Time frame: Up to 14 days

CLss/F of DWC202313 and DWC202314

Time frame: Up to 14 days

Vdss/F of DWC202313 and DWC202314

Time frame: Up to 14 days

PTF of DWC202313 and DWC202314

Time frame: Up to 14 days

Central Contacts

Seung-Hyun Kang, MD, Ph D

CONTACT

070-4665-9490 juspa@newyjh.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.